GRAIL Inc. (GRAL) vs Immunovant, Inc. (IMVT)
A side-by-side comparison of GRAIL Inc. and Immunovant, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GRAL
GRAIL Inc.
$139.18HealthcareDelayed quote: Oct 6, 2026, 2:35 PM EDT
IMVT
Immunovant, Inc.
$31.71HealthcareDelayed quote: Oct 6, 2026, 2:35 PM EDT
Total return — GRAL vs IMVT
growth of $100 · dividends reinvested · last 2yGRAL +1028.0% (+235.9%/yr)IMVT +30.1% (+14.1%/yr)GRAL compounded faster over this window
Log scale — wide-divergence pair
GRAL IMVT
GRAL vs IMVT: by the numbers
- •IMVT is the larger company ($6.55B vs $5.97B market cap).
- •Both run net losses; GRAL's is the smaller (-236.95% vs -7585.86% net margin).
Metrics side by side
Valuation
| Metric | GRAL | IMVT |
|---|---|---|
| P/S ratio | 36.14 | 922.48 |
| P/B ratio | 2.35 | 8.90 |
Profitability
| Metric | GRAL | IMVT |
|---|---|---|
| Gross margin | -42.52% | 0.00% |
| Operating margin | -362.95% | 0.00% |
| Net margin | -236.95% | -7585.86% |
| ROE | -15.40% | -73.19% |
| ROIC | -20.26% | -76.00% |
Growth (annualized)
| Metric | GRAL | IMVT |
|---|---|---|
| Total return CAGR (5Y) | N/A | 29.93% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.